Microcap Ledger SELLAS Life Sciences Group, Inc. $SLS
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- New York, NY
- Fiscal year end
- December 31
- Shares outstanding
- 201,945,709 [10-Q 2026-08-11]
What the company doesAI summary of filing
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company developing cancer therapeutics. The company's lead product candidate, galinpepimut-S (GPS), is a peptide immunotherapy targeting the WT1 antigen currently in Phase 3 clinical trials for acute myeloid leukemia. Its second product candidate, SLS009 (tambiciclib), is a CDK9 inhibitor in Phase 2 development for hematologic and solid tumors. The company is pre-revenue and funds operations through licensing agreements, milestone payments, and capital raises, with revenue potential dependent on regulatory approval and commercialization of its product candidates. [10-K 2026-03-19]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $0.00 | −$18.01M | −$16.43M | $138.34M | [10-Q 2026-08-11] |
| FY ended Dec 2025 | — | −$26.86M | −$28.39M | $71.79M | [DEF 14A 2026-04-23] |
| FY ended Dec 2024 | — | −$30.88M | −$35.40M | $13.89M | [DEF 14A 2026-04-23] |
- Quarterly cash burn
- −$8.22M
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-12 | 70,381,979 | [10-Q 2024-11-13] |
| 2025-03-19 | 90,846,692 | [10-K 2025-03-20] |
| 2025-05-12 | 99,777,487 | [10-Q 2025-05-13] |
| 2025-08-11 | 105,297,469 | [10-Q 2025-08-12] |
| 2025-11-11 | 142,442,239 | [10-Q 2025-11-12] |
| 2026-03-18 | 179,582,574 | [10-K 2026-03-19] |
| 2026-05-11 | 186,032,574 | [10-Q 2026-05-12] |
| 2026-08-10 | 201,945,709 | [10-Q 2026-08-11] |
- Shelf registration
- S-3ASR filed 2026-03-20 [S-3ASR 2026-03-20]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-16 | Stergiou Angelos M. | grant | 1,065,000 | — | [4 2026-06-18] |
| 2026-01-07 | Varian John | grant | 50,000 | — | [4 2026-01-09] |
| 2026-01-07 | Van Nostrand Robert L | grant | 50,000 | — | [4 2026-01-09] |
| 2026-01-07 | Scheinberg David A | grant | 50,000 | — | [4 2026-01-09] |
| 2026-01-07 | Cicic Dragan | grant | 300,000 | — | [4 2026-01-09] |
| 2026-01-07 | Burns John Thomas | grant | 300,000 | — | [4 2026-01-09] |
| 2026-01-07 | Kalin Katherine Bach | grant | 50,000 | — | [4 2026-01-09] |
| 2026-01-07 | Wasman Jane | grant | 50,000 | — | [4 2026-01-09] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-11 | 8-K | Results of operations |
| 2026-08-11 | 10-Q | Quarterly report |
| 2026-08-07 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-31 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-27 | 8-K | Results of operations; Other events |
| 2026-06-25 | 8-K | Director or officer change |
| 2026-06-18 | 8-K | Shareholder vote results |
| 2026-06-02 | 8-K | Other events |
| 2026-05-12 | 8-K | Results of operations |
| 2026-05-12 | 10-Q | Quarterly report |
| 2026-04-24 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-04-23 | DEF 14A | Proxy statement |
Alerts for $SLS
Email me when SELLAS Life Sciences Group, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.